SCHEDULE: Panacea Venture Increases Stake in Connect Biopharma to 25.1%

Panacea Venture Healthcare Fund II, L.P. has increased its beneficial ownership in Connect Biopharma Holdings Limited to 25.1% through recent open market purchases of American Depositary Shares.

Summary

• Panacea Venture Healthcare Fund II, L.P. and its related entities (Panacea Innovation Limited, Panacea Venture Healthcare Fund II GP Company, Ltd., and James Huang) collectively beneficially own 13,950,000 Ordinary Shares of Connect Biopharma Holdings Limited.
• This represents 25.1% of the Issuer's Ordinary Shares outstanding, based on 55,561,056 Ordinary Shares as of April 30, 2025.
• Since July 1, 2024, Panacea Venture Healthcare Fund II, L.P. acquired 540,000 American Depositary Shares (ADSs) at a weighted average price of $1.3621 per ADS.
• Within the last 60 days, 170,000 ADSs were purchased in open market transactions on the Nasdaq Global Market.
• Specific purchases include 25,000 ADSs on July 11, 2025, at $1.3615; 20,000 ADSs on July 14, 2025, at $1.4069; and 125,000 ADSs on July 17, 2025, at $1.7201.
• Funds for these purchases were sourced from capital contributions from the fund's partners.

Sentiment

Score: 8

Explanation: The increased stake by a major institutional investor, particularly with recent purchases at higher prices, signals strong confidence in the company's value and future, which is generally a very positive indicator for the stock.

Positives

• Increased stake by a significant institutional investor (Panacea Venture) indicates continued confidence in Connect Biopharma Holdings Limited.
• Recent purchases were made at increasing prices, with the latest significant purchase at $1.7201, suggesting a positive view on the stock's value.

Risks

• No specific risks related to the company's operations or financial health are detailed in this Schedule 13D filing. The filing is solely about beneficial ownership.

Future Outlook

This Schedule 13D filing does not contain any forward-looking statements or guidance regarding Connect Biopharma Holdings Limited's future performance or strategic direction.

Industry Context

This filing indicates a significant institutional investor's continued accumulation of shares in a biopharma company, which can be seen as a vote of confidence in the company's long-term prospects within the competitive biopharmaceutical industry. Such increased stakes by venture funds are common in the biotech sector, often preceding or following key clinical milestones or strategic developments.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not contain financial results or operational data that can be directly compared to industry benchmarks or specific comparable companies/projects.
• The increase in stake by Panacea Venture, a healthcare-focused fund, aligns with typical investment strategies of venture capital firms in the biopharma sector, where long-term positions are built in promising companies.

Related Party Transactions

• James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. This structure establishes a clear chain of control and beneficial ownership among the reporting persons.

Stakeholder Impact

• Shareholders: The increased stake by a major institutional investor may instill greater confidence among existing shareholders and attract new investors, potentially leading to positive share price movement.
• Company Management: The significant ownership by Panacea Venture could imply increased oversight or strategic alignment with a major investor, potentially influencing corporate decisions.

Key Dates

Recommendation

Keywords

Connect Biopharma Holdings Limited, Panacea Venture, Schedule 13D, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Institutional Investment, Biopharma, SEC Filing